Tuftsin analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-10 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Recent research efforts are being devoted to the homogeneous recycling by Grouped Actinides Extraction (GANEX), which consists in a previous uranium recovery (GANEX 1) and a successive group separation of plutonium, neptunium, americium and curium actinide ions (GANEX 2).
In 2026, the government introduced the Building Homes and Improving Transportation Infrastructure Act, which seeks to do, among other things, "harmonize" transit fares across the Greater Toronto and Hamilton Area by requiring agencies to adopt a single unified fare structure. The legislation will also increase penalties for fare evaders. Ford had previously implemented changes called "One Fare", which makes transit riders only pay once when transferring between the TTC and GO Transit, Brampton Transit, Durham Region Transit, MiWay, and York Region Transit. In March 2026, it was announced that the municipal, provincial, and federal governments would fund the Waterfront East LRT project.
Alberto E. Paniz-Mondolfi (born April 12, 1976) is a Venezuelan pathologist, epidemiologist, and molecular medicine researcher. Currently he is a pathologist and assistant professor in New York City and is affiliated with multiple hospitals in the area, including Mount Sinai Morningside and Mount Sinai West Hospitals and Mount Sinai Hospital. Also, he is the Academic Director and Founder of The Venezuelan Science Incubator (incubadorave.org), a group focused on infectious diseases research and awareness based in Venezuela.
== Erinacine C == Erinacine C has also been observed to activate the transcription factor Nrf2 and has been observed to play a role in neurogenesis and neuroplasticity. Stimulator of NGF synthesis in vitro((299.1 ± 59.6) pg/mL at 1.0 mmol/L)
Sources: en.wikipedia.org
=== Freeze drying === Originally introduced in 1813 by William Hyde Wollaston to the Royal Society in London, it was not until the late 80's the freeze-drying industry discovered the allurement and longevity of freeze-dried flowers. Freeze-dried flowers are fresh flowers that have been specially dried to preserve their natural shape and color. Freeze drying is accomplished by a process called sublimation. It requires a special freeze-drying machine. It involves first freezing the flowers at 100K for at least 12 hours. A vacuum pump slowly pulls the moisture out of the flowers as a vapor in one chamber, and then the vapor condenses as ice in another chamber. Because of this process, the shape and natural color of the flower is maintained. It has been found that certain flowers retain their color well despite the fact they have been freeze-dried. Apparently, such flowers retain their color due to the tissue composition of the petals, leaves, and the like. Carnations, African violets, roses, asparagus and other ferns, and baby's breath exhibit good color retention notwithstanding the dehydration during the freeze-drying process. Those floral pieces which either dull or fade from dehydration may be given color by utilization of a florist's spray tint. This spray coloring restores the lost color which, in the sealed environment of the glass container of the final product, retains its given color along with the natural color of the other pieces.
Since its half-life of 5.5 to 26 hours is quite long, consciousness would take a long time to return. In veterinary medicine, sodium thiopental is used to induce anesthesia in animals. Since it is redistributed to fat, certain lean breeds of dogs such as sighthounds have prolonged recoveries from sodium thiopental due to their lack of body fat. Conversely, obese animals recover rapidly, but it takes much longer for the drug to be entirely removed (metabolized) from their bodies. Sodium thiopental is always administered intravenously, as it can be fairly irritating to tissue and is a vesicant; severe tissue necrosis and sloughing can occur if it is injected incorrectly into the tissue around a vein.
Badly decomposing bodies, trauma cases, frozen, or drowned bodies, and those to be transported over long distances also require special treatment beyond that for the "normal" case. The restoration of bodies and features damaged by accident or disease is commonly called restorative art or demisurgery, and all qualified embalmers have some degree of training and practice in it. For such cases, the benefit of embalming is startlingly apparent. Normally, a better result can be achieved when a photograph and the decedent's regular make-up (if worn) are available to help make the deceased appear more as they did when alive. Embalming autopsy cases differs from standard embalming because the nature of the post-mortem examination irrevocably disrupts the circulatory system, due to the removal of the organs and viscera. In these cases, a six-point injection is made through the two iliac or femoral arteries, subclavian or axillary vessels, and common carotids, with the viscera treated separately with cavity fluid or a special embalming powder in a viscera bag. Long-term preservation requires different techniques, such as using stronger preservatives and multiple injection sites to ensure thorough saturation of body tissues.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.